Chris Gibson, Recursion CEO (Vaughn Ridley/Sportsfile for Web Summit via Getty Images)

Re­cur­sion will take its AI plat­form pub­lic in lat­est IPO fil­ing, while rare heart mu­ta­tion biotech jumps on SPAC train

Ed­i­tor’s note: In­ter­est­ed in fol­low­ing bio­phar­ma’s fast-paced IPO mar­ket? You can book­mark our IPO Track­er here.

The IPO mar­ket con­tin­ues to churn, with a promi­nent AI drug de­vel­op­er be­com­ing the lat­est biotech to reg­is­ter with the SEC.

Re­cur­sion Phar­ma­ceu­ti­cals filed its S-1 pa­per­work late Mon­day, com­ing about six months af­ter com­plet­ing a $239 mil­lion Se­ries D round and se­cur­ing a deal with Bay­er worth up to $1 bil­lion. The Salt Lake City-based biotech is pen­cil­ing in a $100 mil­lion IPO raise for now, but could have its sights set on a much high­er fig­ure.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.